Oxytocin Ameliorates Remote Liver Injury Induced by Renal Ischemia-Reperfusion in Rats

Renal ischemia-reperfusion (IR) causes remote liver damage. Oxytocin has anti-inflammatory and antioxidant effects. The main purpose of this study was to evaluate the protective function of oxytocin (OT) in remote liver damage triggered by renal IR in rats. Twenty four rats were randomly divided into four different groups, each containing 8 rats. The groups were as follows: (1) Sham operated group; (2) Sham operated+OT group (3) Renal IR group; (4) Renal IR+OT group. OT (500microg/kg) was administered subcutaneously 12 and 24 hours before and immediately after ischemia. At the end of experimental procedure, the rats were sacrificed, and liver specimens were taken for histological assessment or determination of malondialdehyde (MDA), total oxidant status (TOS), total antioxidant status (TAS), paraoxonase (PON-1) activity and nitric oxide (NO). The results showed that renal IR injury constituted a notable elevation in MDA, TOS, Oxidative stress index (OSI) and significantly decreased TAS, PON-1 actvity and NO in liver tissue (p<0.05). Additionally renal IR provoked significant augmentation in hepatic microscopic damage scores. However, alterations in these biochemical and histopathological indices due to IR injury were attenuated by OT treatment (p<0.05). These findings show that OT ameliorates remote liver damage triggered by renal ischemia-reperfusion and this preservation involves suppression of inflammation and regulation of oxidant-antioxidant status.

Expression of p53 oncoprotein and bcl-2 in renal cell carcinoma

The aim of the present study was to investigate the significance of p53 and bcl-2 as prognostic factors among others in renal cell carcinoma patients. We evaluated the stages, histological grades, tumor diameters, cellular patterns and the presence of mutant p53 protein and bcl-2 overexpression in 57 cases of renal cell carcinoma [RCC]. Kaplan-Meier and log-rank tests estimated the survival function of each parameter. The study was carried out in the Department of Pathology and the Department of Urology, Faculty of Medicine, Dicle University Hospital, Diyarbakir, Turkey, in 2003. The p53 mutation was 35% and bcl-2 overexpression incidence was 89.4% in the RCC cases included in the study. The 5-year disease specific survival rates of mutant p53 positive was 46.6% and p53 negative cases were 83.3%, [p=0.0063]. There was no pathological parameter associated in bcl-2, and it has no prognostic significance. The tumor stage, grade, diameter and p53 mutations affect the survival of RCC cases. The bcl-2 staining did not play any role to estimate patients at high risk of the disease progression